

Newport Beach and Birch Street

Clinical Research Treatment Trial Flowchart



AML NEWLY DIAGNOSED: NON-INTENSIVE

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy
FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar
Coord: S. Osorio
Accrual: 1/5

POLYCYTHEMIA VERA

UCI 21-204

ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

PI: Fleischman
Coord: K. McAbee
Accrual: 1/5

CLL RELAPSED/REFRACTORY: 2L+

UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs
Coord: S. Osorio
Accrual: 2/3

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs
Coord: S. Osorio
Accrual: 1/10



CRC: ADJUVANT

NRG GI005/COBRA
 (SOC vs mFOLFOX6 or CAPOX or surveillance)

PI: Zell
 Coord: L. Aguilar
 Accrual: 2/5

GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC

ECOG EA2183
 (SOC + XRT)

PI: Seyedin
 Coord: J. Koff
 Accrual: 0/10

UCI 21-193
 (FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))

PI: Dayyani
 Coord: M. Nguyen
 Accrual: 1/12

GASTRIC/GEJ: NEOADJUVANT

UCI 21-191
 (SOC therapy with ctDNA testing)

PI: Dayyani
 Coord: A. Luna
 Pending activation



NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli
Coord: B. Sanchez/C. Carlton
Accrual: 64/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli
Coord: B. Sanchez
Accrual: 48/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

ADJUVANT

ALLIANCE A011801 (HER2+)

Antibody drug conjugate + kinase inhibitor

PI: Parajuli
Coord: Stephany Ruiz
Accrual: 2/5

UCI 22-141 (TNBC)

PDL-1 inhibitor

PI: Parajuli
Coord: Stephany Ruiz
Accrual: 0/5



■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)
PI: Parajuli; Coord: K. Kaminski/D. Huttar
Accrual: 1/5

UCI 19-145 (HR+/HER2-)

CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor
PI: Mehta; Coord: S. Ruiz
Accrual: 9/20

UCI 21-212 (TNBC)

Antibody drug conjugate
PI: Parajuli; Coord: St. Ruiz/J. Miranda
Accrual: 0/3

ETCTN 10551 (germline BRCA 1/2+)

Hu5F9-G4 (magrolimab) recombinant humanized anti-CD47 mAb IgG4
PI: Parajuli; Coord: A. Chavez
Accrual: 0/5

UCI 22-139 (HR+/HER2-)

PI3K/mTOR inhibitor
PI: Parajuli; Coord: Alexis Chavez
Accrual: 2/5

UCI 22-114 (ER+/HER2-)

Proteasome-mediated degradation
PI: Parajuli; Coord: Alexis Chavez
Accrual: 3/5

HCC: LOCOREGIONAL

UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani
Coord: Han Nguyen
Accrual: 15/35

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani
Coord: H. Nguyen
Accrual: 5/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani
Coord: H. Nguyen
Accrual: 4/8



MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 68/90

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

SARCOMA: RECURRENT

ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow
Coord: B. Huynh
Accrual: 1/5



KRAS

UCI 22-75

KRAS targeted Vaccine

PI: Valerin
Coord: M. Duron
Accrual: 1/7

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

CLDN18.2

UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani
Coord: K. Ghio
Accrual: 10/17

NON-TREATMENT

UCI 20-101

(Biospecimen Collection for patients planned to start treatment)

PI: Senthil
Coord: N. Arechiga
Accrual: 53/80

SWOG S1823

Low risk group (Stage I/IA)
Moderate risk group (Stage IIA/IB)
High risk group (nonseminoma Stage IS only)

PI: Rezazadeh
Coord: K. Cung
Accrual 3/8